Date: 2011-05-02
Type of information: R&D agreement
Compound: undisclosed
Company: Dyadic (USA) Engen Bio (USA) Sanofi Pasteur (France)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Dyadic International has announced that its R&D subsidiary, Dyadic Nederland B.V., has entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc. Under the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland’s R&D facility in Wageningen which will utilize Dyadic’s proprietary and patented C1 Platform Technology for certain vaccine applications. This platform based on Dyadic’s patented and proprietary C1 fungus enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. It can also be used to screen for the discovery of novel genes and proteins.
The research is anticipated to be completed in six to twelve months. All other terms of the research collaboration are confidential.
Financial terms:
Latest news:
